SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits.

Notably, in this selected population, canagliflozin effectively reduced CV death, even if only borderline significant [hazard ratio (HR), 0.78; 95% CI, 0.61–1.00; P = 0.05].

also in 6,883 other papers

8.3%), did not reach statistical significance.

also in 75,281 other papers